Shanghai Haoyuan Chemexpress Co., Ltd.
Country: 
China (Mainland)
Business Type: Trading Company
This is the LookChem platform customer service phone number. The supplier hasn't provided their contact information yet. If you need assistance, please reach out to us!
As oncology drug development advances, overcoming tumor heterogeneity and resistance remains a major challenge. One promising approach is the development of dual-payload antibody-drug conjugates (ADCs), which incorporate two distinct therapeutic agents with different mechanisms of action into a single ADC.
According to ApexOnco’s oncology pipeline data, the nascent field of dual-payload ADCs has seen a surge, with 23 new assets entering development over the past six months, representing 40% of all such ADCs ever reported. The surge in interest in this novel class of ADCs is reflected in AACR 2025 abstracts, promising 14 preclinical presentations on dual-payload ADCs[1][2].
Among the posters are two featuring Chengdu Kanghong's TROP2-targeting molecule KH815, which according to a new listing on ClinicalTrials.gov is due to start a phase 1 trial on April 30, making it the first dual-payload ADC to be tested in humans[3].
Table Summarizing Dual-Payload ADCs To Be Presented at AACR 2025
Source: Oncology Pipeline(ApexOnco)
The design of dual-payload ADCs requires careful consideration. It is not merely a matter of attaching two payloads to a monoclonal antibody. Rather, the linker chemistry, payload synergy, and targeted delivery must all be finely tuned to achieve therapeutic efficacy and manageable toxicity.
The rationale behind dual-payload ADCs is to overcome the two major resistance mechanisms observed in ADC-treated patients: loss of the target antigen and resistance to a single payload. Whether this strategy will translate into meaningful clinical benefit remains to be seen—but with the first dual-payload ADC entering clinical trials this month, the field is poised for rapid advancement and potentially transformative impact in oncology.
https://www.chemexpress.com/information-sheet.html?resources=brochure
Reference：
[1] Oncology Pipeline(ApexOnco)
[2] Beacon
[3] ClinicalTrials.gov
Shanghai Haoyuan ChemExpress Co., Ltd.
T: (+86) 021-58950125 | E: info@chemexpress.com
A: No. 3 Building, No. 1999, Zhangheng Road, Pudong New Area, Shanghai, P.R.China
www.chemexpress.com
